EASI-Related and PASI-Related Clinical Efficacy Endpoints in Atopic Dermatitis and Psoriasis Studies Were Incorrectly Calculated by Lilly and Were Reported Erroneously at EADV 2022
SAN FRANCISCO,.
Nektar Therapeutics’ stock jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli.
Nektar Therapeutics (NKTR) Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Nektar Therapeutics (NASDAQ:NKTR – Get Rating) has been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average twelve-month price objective among brokerages […]
Nektar Therapeutics (NASDAQ:NKTR – Get Rating) has received an average rating of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12 month target price among brokers […]